Immunome Stock Quote IMNM - Stock Price, News, Charts, Message Board, Trades

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

Home
Investing
Stocks
USA
NASDAQ
Immunome Inc (IMNM) Quote

Immunome Inc (IMNM)

14.65

0.03

(0.21%)

Closed May 29 4:00PM

Delayed by 15 minutes

14.65

0.00

( 0.00% )

Pre Market: 4:03AM

Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Current Price

14.65

Bid

14.62

Ask

14.87

Volume

-

0.00 Day's Range 0.00

4.50 52 Week Range 30.958

Market Cap

Previous Close

14.65

Open

-

Last Trade

Last Trade Time

-

Financial Volume

-

VWAP

-

Average Volume (3m)

753,318

Shares Outstanding

42,729,847

Dividend Yield

-

PE Ratio

-5.86

Earnings Per Share (EPS)

-2.5

Revenue

14.02M

Net Profit

-106.81M

Immunome Inc is a biopharmaceutical company. It is engaged in utilizing proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The company's primary focus areas are oncology and infectious... Immunome Inc is a biopharmaceutical company. It is engaged in utilizing proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The company's primary focus areas are oncology and infectious disease, including COVID-19. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.immunome.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

Immunome Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker IMNM. The last closing price for Immunome was $14.65. Over the last year, Immunome shares have traded in a share price range of $ 4.50 to $ 30.958.

Immunome currently has 42,729,847 shares outstanding. The market capitalization of Immunome is $625.99 million. Immunome has a price to earnings ratio (PE ratio) of -5.86.

Immunome Announces Completion of Purchase of Assets from Atreca

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the completion of its purchase of...

Form 4 - Statement of changes in beneficial ownership of securities

Immunome Announces Promotion of Max Rosett to Chief Financial Officer

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the promotion of Max Rosett to Chief...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Immunome Reports First Quarter 2024 Financial Results and Provides Business Update

Integration of AL102 and IM-1021 completed Topline data for Phase 3 RINGSIDE trial of AL102 expected in second half of 2025 IM-1021 and IM-3050 IND submissions expected in first quarter of 2025...

Immunome to Present at 2024 Bank of America Healthcare Conference

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.08	-0.543109300747	14.73	14.99	13.99	801900	14.42587033	CS
4	-0.14	-0.946585530764	14.79	16.79	13.515	789449	14.71158469	CS
12	-12.16	-45.3562103693	26.81	30.958	13.515	753318	17.96893323	CS
26	7.11	94.2970822281	7.54	30.958	6.93	670808	18.34837456	CS
52	9.53	186.1328125	5.12	30.958	4.5	408758	16.31226984	CS
156	-6.34	-30.2048594569	20.99	30.958	2.09	212856	15.52568856	CS
260	-1.01	-6.44955300128	15.66	63.78	2.09	202350	17.44797528	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
INXBInhibrx Biosciences Inc	13.90 (75.28%)	450
SMFLSmart for Life Inc	$ 6.19 (58.31%)	745.4k
HLTHCue Health Inc	$ 0.0841 (53.47%)	30.2M
NUZENuZee Inc	$ 2.60 (49.43%)	41
TWOU2U Inc	$ 0.37 (33.57%)	46
LUCYInnovative Eyewear Inc	$ 0.7199 (-24.14%)	1.27M
SNOASonoma Pharmaceuticals Inc	$ 0.2134 (-17.92%)	201.14k
ONCOOnconetix Inc	$ 0.243 (-17.60%)	309.64k
MGRMMonogram Technologies Inc	$ 1.77 (-12.81%)	202
BNAIBrand Engagement Network Inc	$ 2.34 (-11.36%)	52.58k
HLTHCue Health Inc	$ 0.0841 (53.47%)	30.2M
VERBVerb Technology Company Inc	$ 0.2094 (29.90%)	25.63M
GWAVGreenwave Technology Solutions Inc	$ 0.0501 (1.42%)	9.85M
FFIEFaraday Future Intelligent Electric Inc	$ 0.4134 (-6.93%)	5.77M
KTRAKintara Therapeutics Inc	$ 0.3319 (22.02%)	2.58M

Monksdream

Monksdream 2 months ago

IMNM 10Q due 3/22

Monksdream

Monksdream 3 months ago

IMNM new 52 week hi

Monksdream

Monksdream 4 months ago

IMNM new 52 week high

OncoJock

OncoJock 6 months ago

Agree.

Wish there were most posts on this board.

Wondering who might be the next big customer to sign a major discovery and commercialization contract with IMNM, after AbbVie?

Also wondering if IMNM is doing any discovery/testing/research related to bispecific antibodies, as opposed to antibody-drug conjugates. Bispecifics are HOT HOT HOT in lymphoma and myeloma.

-- OJ

OncoJock

OncoJock 6 months ago

Laster

Laster 8 months ago

Hopefully the vote passed.
I think this biotech combined company can be a huge success.
Siegall has proven he can build a biotech company.
This will be fun to watch.

Laster

Laster 8 months ago

I believe merger news tomorrow along with huge financing.
Clay B. Siegall To become chairman and CEO of combined company.
He founded Seagen which just sold for $40 billion to Pfizer.
Their innovative technology from Professor Philip S. Low (Purdue University).
Look at Professor Low accomplishments. Unreal.
Watching closely because this might become a huge biotech company.

wiwineguy

wiwineguy 11 months ago

Ha, sold in fall of 21 for $25.

makinezmoney

makinezmoney 11 months ago

$IMNM: Now 10.40 !!!!!!!!!!!

Booooooooooooyakashaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa

Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies

GO $IMNM

makinezmoney

makinezmoney 11 months ago

$IMNM: Boooommmmmmmmmmmmmmm.......now $8.50

Offfffffffffff she goes.

Nice boomer

GO $IMNM

Awl416

Awl416 11 months ago

Immunome and Morphimmune Announce Definitive Merger Agreement and Simultaneous Private Placement Investment of $125 Million to Develop Targeted Cancer Therapies

wiwineguy

wiwineguy 3 years ago

you don't know crap majorbankz. you keep saying i "heard" this, and I "heard" that. can you be any more vague. stfu

Harbor6460

Harbor6460 3 years ago

They cannot dilute on the bid. Only the ask

Pedro2004

Pedro2004 3 years ago

Pulled down to under $20.00

Pedro2004

Pedro2004 3 years ago

They pulled this down to under $21.00

I'm back-in at $21.00

Major_Bankz

Major_Bankz 3 years ago

$22.50 U worry too much, should be $25+ this afternoon IMO

Pedro2004

Pedro2004 3 years ago

I thought this was going to break today. But it' just jumped over $22 -- let's see if that holds.

Pedro2004

Pedro2004 3 years ago

This run could have broke $30 today. But the company killed-it.

Major_Bankz

Major_Bankz 3 years ago

yep, shorties portfolio will get destroyed here.

Pedro2004

Pedro2004 3 years ago

The dilution is going to kill this run.

Pedro2004

Pedro2004 3 years ago

Looks like the company is dumping shares on the bid.

Major_Bankz

Major_Bankz 3 years ago

I don't think PFE and MRNA can claim the same effectiveness for DELTA, plus time to buy is during development not after just like when MRNA was at $20. IMO

Major_Bankz

Major_Bankz 3 years ago

Delta is a BIG problem, IMNM may catch up to PFE and MRNA. IMO

Major_Bankz

Major_Bankz 3 years ago

Immunome was awarded a $17.6 million technology award from the U.S. Department of Defense's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), in collaboration with the Defense Health Agency, to support Immunome’s COVID program.

Given the near-term potential for a resurgence of COVID-19 infections driven by emerging variants, Immunome intends to explore opportunities to expedite the development of this potential therapeutic. The Company plans to submit an IND application with the U.S. Food and Drug Administration (FDA) this quarter.

Major_Bankz

Major_Bankz 3 years ago

IMNM $21 Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes the SARS-CoV-2 Delta Variant in Pre-clinical Testing

Delayed Upgrade Clock

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions